Category Archives: Companies

Mikros Announces $ 1.1 Million Navy Production Order for ADEPT Advanced Maintenance Systems

Mikros Systems Corporation (MKRS) announced today that it has received the first Delivery Order under its recent multi-year $35M contract with the Naval Surface Warfare Center in Crane, IN.

The order covers eleven new production deliveries of Mikros’ Adaptive Diagnostic Electronic Portable Testset (ADEPT) and is valued at $1.1M. The ADEPT units will be produced at the Mikros Manufacturing and Depot Center in Largo, FL and be delivered to the Navy later this year.

“We are excited and ready to ramp up the ADEPT production line here in Largo,” said Mark Laureigh, Mikros Director of Operations. “Having served in the U.S. Navy maintaining and operating an AN/SPY-1 radar system, I know full well the current value and future potential ADEPT brings to our sailors. We are proud for each opportunity we have to serve the men and women of our armed forces.”

The Mikros Systems Manufacturing and Depot Center in Largo, Florida was established in 2009 to manufacture and provide sustainment and logistics support for the ADEPT system. The center has produced and delivered over 200 systems to the U.S. Navy and provides continuing life-cycle support for the systems including, calibration, repair, and training.

For more information on Mikros Systems’ manufacturing capabilities, please visit the Mikros Systems website: http://www.mikrossystems.com.

Capstone Companies, Inc. Reports Record Revenue of $8.9 million

Highlights:
~ Achieved record quarterly revenue of $8.9 million
~ Gross margin expanded 5.5 points to 23.9% of sales
~ Operating leverage drove operating income growth to $1.2 million
~ Net income of $1.1 million increased $1.8 million over a net loss in prior-year period
~ Raised third quarter 2016 revenue guidance to over $9.0 million
~ Uplist to OTCQB Venture Market scheduled for August 22, 2016

DEERFIELD BEACH, FL, August 15, 2016 – Capstone Companies, Inc. (OTC: CAPC, CAPCD) (“Capstone” or the “Company”), a designer of innovative LED lighting solutions including power failure lighting, today reported its financial results for the second quarter 2016.

Stewart Wallach, Capstone’s CEO, commented, “Our strong results for the quarter, with record revenue and solid profitability, reflect the great execution of our growth strategy by the Capstone team. Momentum continues to build with a growing number of consumers purchasing and enjoying our products at record levels. The holiday shopping season is our strongest period in the year, and we are expecting third quarter revenue to meet or exceed what we reported today for the second quarter.

Siyata Mobile Announces Uniden(R) Cellular Boosters Posted Record Sales in June

MONTREAL, QC–(Marketwired – July 07, 2016) – Siyata Mobile Inc. (the “Company” or “Siyata”) (TSX VENTURE: SIM) (OTC PINK: SIMFF) is pleased to announce that its recently acquired subsidiary Signifi Mobile and its portfolio of Uniden® cellular boosters posted ~$450,000 top line revenue in June 2016, representing a ~29% increase in sales over May 2016.

The increase in sales resulted from a combination of online marketing efforts, joint promotions with national retailers, and growing custom installation contracts with commercial clients.

Marc Seelenfreund, CEO of Siyata, states, “We are very pleased with the immediate results of our online marketing and joint campaigns with national retailers. It is very clear that when consumers are shown a cost-effective solution for poor cellular coverage, they become buyers of our boosters. Being fully capitalized allows us to expand and grow our revenue very methodically through increased marketing efforts.”

Interview with SolarWindow CEO, John Conklin

The following is a Q & A with SolarWindow Technologies (WNDW) President and CEO, John A. Conklin

1. SolarWindows are created by applying ultra-thin layers of liquid coating onto glass and flexible plastics. Are there any other substrates you are looking into? Any other uses?

No, at this time the commercialization of SolarWindow focuses on glass and flexible plastic. Plans to coat on substrates other than glass and flexible plastic is planned but not near term.

Commercial development of the SolarWindow products include:

• SolarWindow™ – Commercial, Structural, and Architectural Glass (Commercial) – Flat glass products for installation in new commercial towers under construction and replacement windows, glass walls and curtains, and textured and decorative interior glass walls, room dividers, etc

• SolarWindow™ – Residential – A window glass for installation in new residential homes under construction and replacement windows

• SolarWindow™ – BIPV – Components associated with BIPV applications in homes, buildings, and office towers

• SolarWindow™ Retrofit & Flexible Veneer – Transparent, tinted, and flexible veneers that installers can apply directly over top of existing windows on tall towers and skyscrapers

Our primary focus is first on the development and deployment of SolarWindow™-Commercial products.

Vitro Biopharma CEO Letter to Shareholders 2015

11/5/15 VODG went up 121% today after posting this press release

OTCBB: VODG

Dear Shareholders:
Concussion and traumatic brain injury (TBI) are significant health risks that lack modern therapeutic approaches beyond physical therapy and rehabilitation. The TBI incidence in the US is 1.5 to 1.7 million new cases per year and is estimated to cost $75 billion per year in the US only. Concussion is a growing issue within professional athletes including the NFL where significant health problems are derived from football-related concussion. Military service personnel and numerous others are also significantly impacted by TBI. We began development of stem cell activation technology and products during 2014 and expanded these activities in during 2015 to include treatment of concussion. We have developed patent-pending technology for treatment of neurological conditions through the activation of stem cells residing within the body. This is a process for administration of stem cell therapeutic benefit without stem cell transplants.